
-
Vaxart Inc. NASDAQ:VXRT Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart has believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, Norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Location: | Website: vaxart.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
126.7M
Cash
58.71M
Avg Qtr Burn
-12.74M
Short % of Float
5.19%
Insider Ownership
0.85%
Institutional Own.
15.81%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VXA-CoV2-1 (oral pill XBB) Details COVID-19 | Phase 2b Data readout | |
Oral Bivalent Norovirus Vaccine Details Infectious disease, Norovirus | Phase 2 Data readout | |
Monovalent Norovirus Vaccine Details Norovirus, Infectious disease | Phase 2 Update | |
VXA-A1.1 Details Influenza | Phase 2 Update | |
Oral Bivalent Norovirus Vaccine Details Infectious disease, Norovirus | Phase 1 Update |